Sleep Apnea News and Research

RSS

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.

7 Dec 2010

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF).

7 Dec 2010

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee has recommended with an 8-2 vote that the FDA extend the currently approved use of the LAP-BAND® System, Allergan's gastric band, on the basis of a favorable benefit-risk profile for weight reduction in obese adults who have failed more conservative weight reduction alternatives and have a Body Mass Index (BMI) of at least 35 or a BMI ≥30 and at least one comorbid condition.

4 Dec 2010

SLEEP ACCESS to deliver customized driver fatigue programs

Five state trucking associations have already taken decisive action on preparing their membership for a regulation on fatigued driving and the prevalence of sleep apnea in the trucking industry.

3 Dec 2010

Sleep HealthCenters enters agreement with U.S. HealthWorks to provide sleep medicine services

Sleep HealthCenters has entered into an agreement with U.S. HealthWorks to provide sleep medicine services as part of their occupational medicine programs.

2 Dec 2010

FDA approves Inspire to begin STAR clinical trial to evaluate UAS therapy for OSA

Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).

30 Nov 2010

People with OSA are prone to develop atherosclerosis: Study

People with obstructive sleep apnea (OSA), a sleep disorder associated with obesity, have more non-calcified or "bad" plaque in their coronary arteries, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2010

Study finds abdominal fat as a risk factor for osteoporosis, bone loss in women

For years, it was believed that obese women were at lower risk for developing osteoporosis, and that excess body fat actually protected against bone loss. However, a study presented today at the annual meeting of the Radiological Society of North America (RSNA) found that having too much internal abdominal fat may, in fact, have a damaging effect on bone health.

30 Nov 2010

Tips to improve obese children's surgical outcomes and health

The American Society of Anesthesiologists (ASA) is taking action to educate parents about the increased risk of complications faced by obese children undergoing anesthesia. The number of obese children has doubled in the past two decades and tripled among adolescents and the ASA encourages parents to help improve both the surgical outcomes and long-term health of America's youth.

20 Nov 2010

Researchers find structural deficits in gray matter may be associated with daytime sleepiness

Patients with obstructive sleep apnea (OSA) may blame their daytime difficulties on simple sleepiness, but new research suggests that their brains may be to blame. Specifically, their cognitive challenges may be caused by structural deficits in gray matter, brought on by the intermittent oxygen deprivation that comes with OSA. The good news is that these deficits may be partially or fully reversible with early detection and treatment, according to Italian researchers

15 Nov 2010

Acute sleep deprivation increases inflammation: Research

People who sleep poorly or do not get enough sleep have higher levels of inflammation, a risk factor for heart disease and stroke, researchers have found.

15 Nov 2010

Cortex third quarter net loss decreases to $528,000

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $528,000, or $0.01 per share, for the quarter ended September 30, 2010, compared with a net loss applicable to common stock of approximately $3,243,000 or $0.06 per share, for the prior year quarter.

12 Nov 2010

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

VIVUS closes sale of MUSE business to Meda

VIVUS, Inc. today announced that it has closed the sale of its MUSE business to Meda. Under the purchase agreement, Meda acquired the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

8 Nov 2010

Endocrine Society unveils new guideline on endocrine and nutritional management of post-bariatric surgery patients

The Endocrine Society released a new clinical practice guideline for the nutritional and endocrine management of adults after bariatric surgery, including those with diabetes mellitus. The guideline features a series of evidence-based clinical recommendations developed by an expert task force. The guideline is published in the November 2010 issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society.

4 Nov 2010

Most hospital patients at high risk for obstructive sleep apnea

Eighty-one percent of hospital patients are at high risk for obstructive sleep apnea, a Loyola University Health System study has found.

2 Nov 2010

Researchers analyze how sleep disorders affect risk perception in driving

Within the framework of a recent research project, University of Granada researchers will analyse how sleep disorders affect risk perception in driving. To such purpose, three last-generation simulators provided by the Faculty of Psychology will be employed.

29 Oct 2010

VIVUS receives FDA CRL for QNEXA NDA

VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

29 Oct 2010

AZ-TMJ develops effective treatment for migraine headaches

AZ-TMJ is once again leading the way in innovative and effective treatments for severe cases of Temporomandibular Joint Disorders or TMD. AZ-TMJ has developed a variety of highly effective treatments to greatly reduce the frequency and severity of migraine headaches for a large percentage of sufferers. Approximately 16% to 17% of the population suffers from migraine headaches, which often have a debilitating effect on suffers' daily lives.

27 Oct 2010

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.

25 Oct 2010

Sleep Apnea News and Research

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

SLEEP ACCESS to deliver customized driver fatigue programs

Sleep HealthCenters enters agreement with U.S. HealthWorks to provide sleep medicine services

FDA approves Inspire to begin STAR clinical trial to evaluate UAS therapy for OSA

People with OSA are prone to develop atherosclerosis: Study

Study finds abdominal fat as a risk factor for osteoporosis, bone loss in women

Tips to improve obese children's surgical outcomes and health

Researchers find structural deficits in gray matter may be associated with daytime sleepiness

Acute sleep deprivation increases inflammation: Research

Cortex third quarter net loss decreases to $528,000

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

VIVUS closes sale of MUSE business to Meda

Endocrine Society unveils new guideline on endocrine and nutritional management of post-bariatric surgery patients

Most hospital patients at high risk for obstructive sleep apnea

Researchers analyze how sleep disorders affect risk perception in driving

VIVUS receives FDA CRL for QNEXA NDA

AZ-TMJ develops effective treatment for migraine headaches

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News